DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued to investors on Sunday. The brokerage set a “hold” rating on the stock.

A number of other brokerages have also recently weighed in on DBVT. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of DBV Technologies in a research note on Thursday, August 1st. JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of DBV Technologies in a research note on Tuesday, September 24th.

DBV Technologies Trading Down 2.3 %

NASDAQ DBVT opened at $0.69 on Friday. The company has a 50-day moving average price of $0.81 and a two-hundred day moving average price of $1.01. The stock has a market cap of $66.92 million, a price-to-earnings ratio of -0.83 and a beta of 0.67. DBV Technologies has a 52 week low of $0.50 and a 52 week high of $2.48.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). The business had revenue of $1.16 million during the quarter, compared to the consensus estimate of $1.42 million. DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. During the same period last year, the company earned ($0.26) earnings per share. As a group, equities research analysts expect that DBV Technologies will post -1.43 earnings per share for the current fiscal year.

Institutional Trading of DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. increased its holdings in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the quarter. DBV Technologies accounts for 0.2% of Yiheng Capital Management L.P.’s holdings, making the stock its 15th biggest position. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.